The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.
 
Victor Moreno Garcia
No Relationships to Disclose
 
Emiliano Calvo
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Celgene; Cerulean Pharma; EUSA Pharma; Janssen-Cilag; Nanobiotix; Novartis; Pierre Fabre; PsiOxus Therapeutics; Seagen
Speakers' Bureau - Novartis
Research Funding - Abbvie; Amcure; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; H3 Biomedicine; Incyte; Janssen Oncology; Kura Oncology; Lilly; Loxo; Macrogenics; Menarini; Merck; Merck Serono; Merus; Millennium; Nanobiotix; Nektar; Novartis; Pfizer; PharmaMar; Principa Biopharma; PsiOxus Therapeutics; Puma Biotechnology; RigonTEC; Roche/Genentech; Sanofi; Synthon; Taiho Pharmaceutical; Tesaro
Travel, Accommodations, Expenses - Celgene; Novartis
 
Maria Eugenia Olmedo Garcia
No Relationships to Disclose
 
Marta Gil Martin
No Relationships to Disclose
 
Raid Aljumaily
No Relationships to Disclose
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Lee S. Rosen
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst)
 
Petra Rietschel
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Honoraria - Regeneron
 
Kosalai Kal Mohan
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Jingjin Li
Employment - Novartis; Regeneron
Stock and Other Ownership Interests - Novartis; Regeneron
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Merck; Regeneron
 
Tracey Rowlands
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - McGill Unversity (I)
 
Minjie Feng
Employment - Bayer; Regeneron
Stock and Other Ownership Interests - Bayer; Regeneron
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Consulting or Advisory Role - Egenix
Research Funding - AstraZeneca/MedImmune; Novartis; Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron (I)